Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease

• Status: Completed
• Trial end date: 2010-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Subjects must be 18- 75 years old and have a history of both inflammatory bowels disease (Crohn's or ulcerative colitis) and pyoderma gangrenosum.

This is a 6 month open label study of an intravenous (IV) medication. Visits occur every 2 weeks initially, then every 1-2 months later in the study.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospitals Cleveland Medical Center
• Collaborator: Centocor, Inc.
• Treatments: Infliximab

Criteria

Inclusion Criteria:

• Must Be ages 18-75

• Must have both inflammatory bowel disease and moderate to severe pyoderma gangrenosum

• Must never have received Infliximab for the treatment of pyoderma gangrenosum

Exclusion Criteria:

• Have had any previous treatment with monoclonal antibodies other than infliximab used to treat IBD or antibody fragments.

• Have a history of serious infections